公开(公告)号：US20240174679A1

公开(公告)日：2024-05-30

申请号：US18549223

申请日：2022-03-14

申请人： Kaleen Konrad Childers ,  J. Michael Ellis ,  Peter J. Fuller ,  Hakan Gunaydin ,  Jack D. Scott ,  Haiqun Tang ,  Charles S. Yeung ,  MERCK SHARP & DOHME LLC

发明人： Kaleen Konrad Childers ,  J. Michael Ellis ,  Peter J. Fuller ,  Hakan Gunaydin ,  Jack D. Scott ,  Haiqun Tang ,  Charles S. Yeung

IPC分类号： C07D487/04 ,  A61K31/4155 ,  A61K31/422 ,  A61K31/427 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/496 ,  A61K31/506 ,  A61K31/5365 ,  A61K31/5377 ,  A61K31/55 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D403/14 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  C07D498/04

CPC分类号： C07D487/04 ,  A61K31/4155 ,  A61K31/422 ,  A61K31/427 ,  A61K31/437 ,  A61K31/4439 ,  A61K31/496 ,  A61K31/506 ,  A61K31/5365 ,  A61K31/5377 ,  A61K31/55 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D403/14 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  C07D498/04

摘要： The present invention is directed to certain (hetero)aroyl 4-aminopyrazole derivatives of Formula (I) and pharmaceutically acceptable salts thereof, wherein A, R1, R2, and R3 are as defined herein, which are potent inhibitors of LRRK2 kinase and may be useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease and other diseases and disorders described herein. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved.

公开(公告)号：US20240083903A1

公开(公告)日：2024-03-14

申请号：US18264468

申请日：2022-02-15

申请人： Jongwon Lim ,  Vladimir Simov ,  Brandon A. Vara ,  Charles S. Yeung ,  Sebastian E. Schneider ,  Erin F. DiMauro ,  Merck Sharp& Dohme LLC

发明人： Jongwon Lim ,  Vladimir Simov ,  Brandon A. Vara ,  Charles S. Yeung ,  Sebastian E. Schneider ,  Erin F. DiMauro

IPC分类号： C07D487/04 ,  A61P35/00 ,  C07D209/34 ,  C07D215/20 ,  C07D217/04 ,  C07D231/56 ,  C07D235/24 ,  C07D235/26 ,  C07D237/28 ,  C07D239/84 ,  C07D263/57 ,  C07D265/36 ,  C07D277/66 ,  C07D317/56 ,  C07D471/04 ,  C07D495/04 ,  C07D498/04 ,  C07D513/04

CPC分类号： C07D487/04 ,  A61P35/00 ,  C07D209/34 ,  C07D215/20 ,  C07D217/04 ,  C07D231/56 ,  C07D235/24 ,  C07D235/26 ,  C07D237/28 ,  C07D239/84 ,  C07D263/57 ,  C07D265/36 ,  C07D277/66 ,  C07D317/56 ,  C07D471/04 ,  C07D495/04 ,  C07D498/04 ,  C07D513/04

摘要： The present invention is directed to a compound of Formula I: or a pharmaceutically acceptable salt thereof, as well as pharmaceutical compositions comprising them and methods of using such compounds or pharmaceutical salts thereof.

公开(公告)号：US20210277009A1

公开(公告)日：2021-09-09

申请号：US17266474

申请日：2019-08-05

申请人： David WITTER ,  Shuhei KAWAMURA ,  Michelle MACHACEK ,  Ryan QUIROZ ,  Michael H. REUTERSHAN ,  Sebastian SCHNEIDER ,  Phieng SILIPHAIVANH ,  Yingchun YE ,  Charles S. YEUNG ,  Merck Sharp & Dohme Corp.

发明人： David Witter ,  Shuhei Kawamura ,  Michelle Machacek ,  Ryan Quiroz ,  Michael H. Reutershan ,  Sebastian Schneider ,  Phieng Siliphaivanh ,  Yingchun Ye ,  Charles S. Yeung

IPC分类号： C07D487/04 ,  C07D519/00

摘要： The present invention provides a compound of Formula (I) Formula (I) or the pharmaceutically acceptable salts thereof, which are PRMT5 inhibitors.

公开(公告)号：US11993602B2

公开(公告)日：2024-05-28

申请号：US17266474

申请日：2019-08-05

申请人： Merck Sharp & Dohme LLC ,  David Witter ,  Shuhei Kawamura ,  Michelle Machacek ,  Ryan Quiroz ,  Michael H. Reutershan ,  Sebastian Schneider ,  Phieng Siliphaivanh ,  Yingchun Ye ,  Charles S. Yeung

发明人： David Witter ,  Shuhei Kawamura ,  Michelle Machacek ,  Ryan Quiroz ,  Michael H. Reutershan ,  Sebastian Schneider ,  Phieng Siliphaivanh ,  Yingchun Ye ,  Charles S. Yeung

IPC分类号： C07D487/04 ,  C07D519/00

CPC分类号： C07D487/04 ,  C07D519/00

摘要： The present invention provides a compound of Formula (I) Formula (I) or the pharmaceutically acceptable salts thereof, which are PRMT5 inhibitors.